SEI Investments
IKT icon

SEI Investments’s Inhibikase Therapeutics IKT Stock Holding History

SEI Investments’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$98.6K Hold
47,962
– – ﹤0.01% 3187
2026
Q2 		$97.4K Hold
47,962
– – ﹤0.01% 3189
2026
Q1 		$80.6K Buy
+47,962
New +$85.2K ﹤0.01% 3128

Other funds holding IKT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Kennondale Capital Management
Kennondale Capital Management Richmond, Virginia $154M AUM 37.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

SEI Investments's IKT Position: Q3 2026 in Review

SEI Investments held its Inhibikase Therapeutics (IKT) position steady in Q3 2026 at 47,962 shares worth $98.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3187.

SEI Investments first reported a position in IKT in Q1 2026 and has held it in 3 quarters since. 38 funds tracked by Wall St. Rank hold IKT as of Q3 2026.

  • SEI Investments held 47,962 shares of Inhibikase Therapeutics worth $98.6K as of Q3 2026.
  • SEI Investments left its Inhibikase Therapeutics share count unchanged in Q3 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q3 2026, its #3187 holding.
  • SEI Investments first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 38 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.

Based on SEI Investments's 13F filing for Q3 2026, filed 10 Nov 2026.